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Introduction
Genital herpes is a chronic, sexually transmitted infection that causes significant morbidity globally. Gen-
ital herpes is primarily caused by herpes simplex virus-2 (HSV-2), a double-stranded DNA virus of  the 
alphaherpesvirus family, and there are over 400 million people affected (1). Upon transmission, the virus 
invades genital epithelial cells and spreads into sensory neurons of  the dorsal root ganglia (DRG). Within 
sensory neurons, HSV-2 enters latency and persists in a relatively quiescent state. Periodically, the virus 
reactivates, leading to viral shedding and the recurrent ulcers characteristic of  genital herpes. Once a latent 
reservoir is established, the host is unable to completely clear the virus, and the infection becomes chronic. 
Thus, understanding the factors that control neuronal infection is vital to preventing chronic disease.
HSV-1, an alphaherpesvirus that is highly related to HSV-2, is typically associated with infection of  
oral mucocutaneous tissues and the development of  cold sores. However, the last few decades have seen 
a rise in the number of  genital herpes cases that are caused by HSV-1. An estimated 140 million people 
have HSV-1 genital herpes, and in developed parts of  the Western world, HSV-1 has overtaken HSV-2 as 
the cause of  genital herpes infections (2–4). Despite a high level of  similarity in tissue tropism and patho-
genesis between the viruses, HSV-1 causes milder genital disease after sexual transmission than HSV-2 and 
is better controlled by the host (5–7). Recurrence rates of  HSV-1 genital herpes are approximately 20% of  
HSV-2 recurrence rates (6, 7), with HSV-1 recurrence dropping rapidly within 2 years of  primary infection 
(7). Currently, the biological basis of  the difference in reactivation frequency of  HSV-1– and HSV-2–medi-
ated genital disease remains unclear.
Animal studies have shown that the establishment of  HSV-1 and HSV-2 infection in the nervous system 
is a key factor in determining recurrent disease outcomes (8–10). Reactivation frequency does not correlate 
with viral replication competence at mucosal barriers during primary infection, as HSV-1 and HSV-2 both 
replicate robustly at multiple sites of  entry (8, 9, 11). Instead, vaginal infection of  guinea pigs demonstrates 
a direct relationship between the quantity of  viral genomes and latency associated transcripts (LAT) with 
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reactivation rates (11–14). Equal amounts of  HSV-1 and HSV-2 inoculum resulted in less viral DNA and 
less LAT expression in the ganglia of  HSV-1–infected guinea pigs, which correlated with less frequent 
reactivation, despite similar levels of  viral replication in the genital mucosa (11). Increasing the HSV-1 
inoculum dose to augment viral DNA levels in the DRG resulted in the equalization of  recurrence rates 
(11), suggesting that reduced reactivation frequency after HSV-1 is mainly due to fewer viral genomes in 
the ganglia, as opposed to an inherent inability of  HSV-1 to infect the genital tract and cause local disease. 
It is unclear whether the HSV-1 reservoir in the DRG is consistently smaller than HSV-2 due to defects in 
replication within the neuron or other virus-intrinsic features regulating latency establishment or whether it 
is a consequence of  distinct host responses against these 2 related viruses.
Adaptive immune responses — particularly T cell responses — are critical for controlling genital HSV 
infection. Virus-specific T cells can be found within active and quiescent lesions of  infected patients (15–
17), and T cell density is predicted to inversely correlate with symptomatic recurrences (18–20). Animal 
studies suggest a division of  labor between CD4+ and CD8+ T cells in response to genital HSV challenge. 
IFN-γ–producing memory CD4+ T cells are primarily responsible for eliminating mucosal viral replication 
(21–24), although memory CD4+ T cells can also provide neuroprotection through an antibody-dependent 
mechanism (25). In contrast, memory CD8+ T cells provide neuroprotection and suppress viral reactivation 
through various effector mechanisms (26–29). The role of  T cells during primary HSV infection — particu-
larly their role in shaping the neuronal reservoir after HSV-1 or HSV-2 infection — is less clear.
To begin addressing the question as to whether the host response accounts for the differences in neuronal 
infection during primary HSV-1 and HSV-2 infection, we examined early innate responses in the vagina and T 
cell responses against these 2 viruses using a mouse model of infection. Vaginal infection with HSV-1, but not 
HSV-2, resulted in the early appearance of mature DCs in the draining lymph node (dLN), as well as rapid acti-
vation and dissemination of IFN-γ–producing T cells. Maturation of DCs after HSV-1 infection was dependent 
upon rapid production of NK-cell dependent IFN-γ in the vagina 1 day postinfection (d.p.i.), which did not 
occur after HSV-2 infection. Accordingly, protection of the peripheral nervous system from HSV-1 infection 
was dependent on both T cells and neuronal responsiveness to IFN-γ. Our results highlight unexpected differ-
ences in the primary immune response against these 2 related viruses and begin to reveal host factors that may 
contribute to disparities in recurrence frequency between HSV-1 and HSV-2 genital herpes.
Results
Vaginal infection with HSV-1 leads to less nervous system infection and milder disease than HSV-2. To dissect 
the host responses against genital HSV-1 and HSV-2 infection, female C57BL/6J mice were first inject-
ed with depot medroxyprogesterone (DMPA, Depo-Provera) to arrest the mice in their estrus cycle 
and enhance susceptibility to viral infection (30). Mice were then intravaginally inoculated with 1 × 
104 plaque forming units (PFUs) of  HSV-2 strain 186 syn+ and HSV-1 strain McKrae, which is highly 
neurovirulent compared with other HSV-1 strains (31, 32). Viral shedding into the vaginal lumen was 
similar between HSV-1– and HSV-2–infected mice during the first 5 days of  infection, with a small but 
significant increase in HSV-2 shedding observed on day 6 (Figure 1A). As expected, viral burden in the 
lumbar-sacral DRG at this time point, which was chosen as the latest time point before HSV-2–infect-
ed mice began to display signs of  morbidity, was substantially lower in mice infected with HSV-1 as 
compared with HSV-2 (Figure 1B). Remarkably, 45% of  the HSV-1–infected mice had ganglia titers 
that were below the limit of  detection, despite robust viral shedding in the vaginal mucosa. As expect-
ed, HSV-1–infected mice also displayed milder genital inflammation compared with HSV-2–infected 
mice (Supplemental Figure 1A; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.134258DS1). Accordingly, less damage in the mucosa was present after HSV-1 
infection compared with HSV-2 infection (Supplemental Figure 1B). None of  the HSV-1–infected mice 
developed signs of  neuro-invasive disease, and all mice survived, in contrast to the low survival rate of  
HSV-2–infected animals (Supplemental Figure 1C). Although we were unable to assess latency due to 
the high mortality rate of  the HSV-2–infected group, measurement of  viral genomes in the ganglia by 
quantitative PCR (qPCR) at 6 d.p.i. directly correlated with the load of  replicating virus (Supplemental 
Figure 2), suggesting that HSV-1 infection would have resulted in a small latent reservoir. Together, our 
data confirm previous studies (8, 9, 11) that have reported decreased disease severity and ganglion titers 
after HSV-1 infection compared with HSV-2 infection, and they establish a model in which to interro-
gate host responses that regulate neuronal infection by HSV.
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Greater numbers of  mature DCs are present in the dLN after vaginal HSV-1 infection. Due to the importance 
of  T cells in neuroprotection after HSV infection (25, 26), we first evaluated the initiation of  the adaptive 
immune response in the dLNs of  the vagina in the first few d.p.i. At 2 d.p.i., the cellularity of  dLNs from 
HSV-1–infected mice was considerably greater than that of  dLNs from mice that were mock infected or 
HSV-2 infected (Figure 2A). To understand the difference in LN cellularity between HSV-1– and HSV-2–
infected mice, we examined the DC compartment within the dLN, as these cells are crucial for both LN 
enlargement and T cell activation (33, 34). DCs in the dLN were identified as CD11chiMHCIIhi, and this 
population was subdivided by expression of  CD103 and CD11b into 3 subsets that distinguish between 
CD11b+ cDC2s and CD103– (double negative, DN) versus CD103+ cDC1s (Figure 2B, Supplemental Fig-
ure 3A) (35). After vaginal HSV-1 infection, total DC numbers were elevated in the dLN at 2 d.p.i. (Figure 
2C). We also observed a significantly higher number of  cells within each of  the 3 DC subsets after HSV-1 
infection than after mock or HSV-2 infection (Figure 2, D–F). Inoculation of  mice with low-passage, pri-
mary clinical isolates of  HSV-1 and HSV-2 showed similar differences in disease and survival as observed 
with laboratory strains (Supplemental Figure 4, A and B), and it also yielded increases in total DC numbers 
and DC subsets in the dLN after HSV-1 infection compared with HSV-2 (Supplemental Figure 5, A–D).
To identify potential differences in DC function after HSV-1 or HSV-2 infection, we examined the mat-
uration status of  the DCs in the dLN by measuring cell surface expression of  the costimulatory molecule 
CD86. CD86 expression was highly upregulated on the total DC population after HSV-1 infection com-
pared with both mock and HSV-2 infection (Figure 2G). When assessing individual DC subsets after HSV-1 
infection, we observed increased CD86 expression on CD11b+ and CD103+ DCs, but not on DN DCs (Fig-
ure 2, H–J). Furthermore, although CD11b+ DC numbers were unchanged after HSV-2 infection compared 
with mock-inoculated animals (Figure 2D), CD86 expression was higher on this subset when compared 
with mock-infected controls (Figure 2H), suggesting that DCs in the dLN of  HSV-2–infected mice were 
not entirely unresponsive. The difference in CD86 expression on DCs from mice infected with HSV-1 
and HSV-2 also was maintained when mice were inoculated with clinical isolates (Supplemental Figure 5, 
E–H). Together, our data show that maturation and accumulation of  DCs in the dLN are observed at an 
early time point after vaginal HSV-1 infection but not after HSV-2 infection.
Rapid IFN-γ production after HSV-1 infection is important for accelerated DC maturation. IFNs are a major com-
ponent of  host defense against pathogens and have a strong impact on the development of  immune responses. 
We hypothesized that any differences in IFN production would likely need to occur very early in order to 
affect DC maturation and numbers in the dLN. Thus, we assessed IFN production in the vagina 1 day after 
inoculation to determine whether differences in IFN expression were associated with the disparity in DC mat-
uration observed after HSV-1 and HSV-2 infection. When we measured IFN-α and IFN-β, 2 type I IFNs, we 
found minimal induction of  either cytokine (Figure 3A), in agreement with previous reports (36, 37). IFN-λ, 
which is a type III IFN whose activity is largely restricted to mucosal surfaces (38), was detected in the vagina 
1 day after both HSV-1 and HSV-2 infection (Figure 3B). However, IFN-λ levels were similar after HSV-1 and 
Figure 1. Vaginal HSV-1 infection leads to lower viral burden in the dorsal root ganglia compared with HSV-2 
infection. Eight-week-old C57BL/6J mice were injected with Depo-Provera and inoculated intravaginally with 1 
× 104 PFU HSV-1 strain McKrae or HSV-2 strain 186 syn+. (A) Vaginal washes were collected from mice daily after 
infection, and replicating virus was measured by plaque assay (HSV-1, n = 17–23; HSV-2, n = 13–22). (B) Ganglia were 
harvested from HSV-1– or HSV-2–infected mice at 6 days postinfection (d.p.i) (HSV-1, n = 22; HSV-2, n = 16). Dashed 
lines in A and B show limit of detection. Data in A and B are pooled from at least 3 independent experiments. 
Horizontal bars show mean, vertical lines show 95% CI. Statistical significance in A was measured by 2-way ANOVA 
with Bonferroni multiple comparisons test on log-transformed data. Statistical significance in B was measured by 
Mann-Whitney U test on log-transformed data. ****P < 0.001.
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HSV-2 infection, indicating that IFN-λ was likely not responsible for differences in DC maturation. Indeed, 
infection of  IFN-λ receptor–deficient (IFN-λR–deficient) animals with HSV-1 had no impact on the expres-
sion of  CD86 on DCs within the dLN compared with WT controls (Supplemental Figure 6, A–D). We next 
evaluated IFN-γ secretion in the vagina at day 1 after HSV-1 and HSV-2 infection, and we discovered robust 
IFN-γ production after HSV-1 but not HSV-2 infection (Figure 3C). Similar patterns of  IFN-γ production 
were observed after infection with different inoculum doses of  HSV-1 and HSV-2 (Figure 3D) and after infec-
tion with clinical isolates (Supplemental Figure 7), suggesting that differential IFN-γ production at 1 d.p.i. was 
a distinguishing feature between these 2 infections and independent of  infectious viral input. Furthermore, 
Figure 2. Greater numbers of mature DCs are present in the draining lymph node after HSV-1 infection than after HSV-2 infection. Eight-week-old 
C57BL/6J females were injected with Depo-Provera and inoculated intravaginally with 1 × 104 PFU HSV-1 strain McKrae, HSV-2 strain 186 syn+, or PBS as a 
control. (A) Total number of live cells in the draining lymph node (dLN) 2 days after infection with HSV-1 (n = 13), HSV-2 (n = 12), or mock (n = 13) inocula-
tion with PBS. (B) Representative flow plots showing gating strategy for DCs in the dLN. Left plot is gated on live NK1.1–Ly6C– cells. Right plot is gated on 
CD11c+MHCII+ cells (DCs). (C–F) Graphs show the number of total DCs (CD11c+MHCII+) (C), CD11b+ DCs (D), CD103+ DCs (E), and CD11b–CD103– (double negative, 
DN) DCs (F) at 2 d.p.i. per dLN (HSV-1, n = 13–17; HSV-2, n = 12; mock, n = 10). (G–J) Graphs show mean fluorescence intensity (MFI) of CD86 expression on 
total DCs (CD11c+MHCII+) (G), CD11b+ DCs (H), CD103+ DCs (I), and DN DCs (J) at 2 d.p.i. in each dLN (HSV-1, n = 10–12; HSV-2, n = 10–11; mock, n = 8). Histograms 
show representative expression of CD86 on each DC subset from mock- (shaded gray), HSV-1– (black), or HSV-2–infected (red) mice; histograms show repre-
sentative data of the graphs directly above. All data are pooled from 3 independent experiments. Horizontal bars indicate geometric mean; error bars show ± 
SD. Statistical significance was measured by 1-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.
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coinoculation with both HSV-1 and HSV-2 led to IFN-γ production that closely resembled that of  HSV-1 
inoculation alone (Figure 3E), indicating that the IFN-γ induction by HSV-1 infection was not suppressed 
by HSV-2 infection at 1 d.p.i. To determine whether neutralization of  the early IFN-γ response after HSV-1 
could alter DC maturation status, we intravaginally treated HSV-1–infected mice with an IFN-γ–neutralizing 
antibody or an isotype control. Upon IFN-γ neutralization after HSV-1 infection, we found that, at 2 d.p.i., 
CD86 expression was markedly reduced on total DCs (Figure 3F), as well as on each DC subset (Figure 3, 
G–I) in the dLN. Thus, our data show that distinct induction of  IFN-γ in the vagina after HSV-1 and HSV-2 
infection is a key factor in determining the maturation status of  DCs.
Early IFN-γ production after HSV-1 infection is driven primarily by NK cells. Early production of  IFN-γ 
after genital HSV-2 infection in mice has been reported to occur at 2 d.p.i., and our infection model con-
firms this finding (Supplemental Figure 8) (39–41). The day 2 production of  IFN-γ after primary HSV-2 
infection is largely dependent on NK cells (39, 41). To test whether these cells were also important for 
IFN-γ production at day 1 after HSV-1 infection, mice were treated with a depleting antibody against 
Figure 3. IFN-γ production occurs early after HSV-1 but not HSV-2 infection. Infections were performed as described in 
Figure 2. IFN-β (mock, n = 10; HSV-1, n = 12; HSV-2, n = 8) and IFN-α (mock, n = 9; HSV-1, n = 11; HSV-2, n = 11) (A), IFN-λ 
(mock, n = 11; HSV-1, n = 10; HSV-2, n = 10) (B), and IFN-γ (mock, n = 15; HSV-1, n = 9; HSV-2, n = 9) (C) were measured at 
1 d.p.i. from vaginal washes. Dashed lines indicate limit of detection. (D) Mice were inoculated with 1 × 105 PFU HSV-1 
(n = 9), 1 × 105 HSV-2 (n = 8), 5 × 103 PFU HSV-2 (n = 8), or 1 × 103 PFU HSV-2 (n = 8), and IFN-γ was measured at 1 d.p.i. 
from vaginal washes. (E) Mice were inoculated with 1 × 104 PFU HSV-1 alone or 1 × 104 PFU HSV-2 alone, or coinoculated 
with 1 × 104 PFU HSV-1 and HSV-2 (n = 9 for all groups). IFN-γ production was measured at 1 d.p.i from vaginal washes. 
In F–I, HSV-1–infected mice were treated intravaginally with 100 μg αIFN-γ neutralizing antibody (n = 8) or isotype 
control (n = 7) 1 d.p.i. CD86 expression on total DC (CD11c+MHCII+) (F), CD11b+ DC (G), CD103+ DC (H), and DN DC (I) was 
measured 2 d.p.i. All data are pooled from 2 independent experiments. Error bars show ± SD. Dashed lines in graphs 
show limit of sensitivity for ELISA assay. Statistical significance was measured by 1-way ANOVA with Tukey’s multiple 
comparisons test (A–E) or 2-tailed Student’s t test (F–I). *P < 0.05, **P < 0.01, ****P < 0.001.
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NK cells (Figure 4, A and B). Antibody-mediated depletion of  NK cells resulted in a marked decrease 
in IFN-γ production after HSV-1 infection, suggesting a critical role for NK cells in rapid, local cytokine 
production (Figure 4C). However, we found no substantial differences in NK cell numbers in the vagina 
when measured at 1 day after HSV-1 or HSV-2 infection, suggesting that accumulation of  NK cells in 
the vagina was similar after inoculation with these 2 viruses (Figure 4D). To determine whether access 
of  NK cells to sites of  infected epithelium might distinguish early responses against HSV-1 and HSV-2, 
we examined the distribution of  NK cells in the vagina after HSV-1 or HSV-2 infection of  Ncr1-Cre × 
ROSA26mTd/mGFP reporter mice (Ncr1mT/mG) (42) (Figure 4E). Strikingly, there was a marked increase 
in the number of  NK cells recruited to infected epithelial cells (Figure 4F) and areas proximal to the 
infected epithelium (Figure 4G) after HSV-1 inoculation compared with HSV-2, suggesting that appro-
priate localization of  NK cells within the vagina may be required for immediate IFN-γ production after 
HSV infection. Together, our data identify an important role for NK cells in mediating very early IFN-γ 
responses after HSV-1, which is absent after HSV-2 genital infection.
Figure 4. NK cells mediate IFN-γ production early after HSV-1 infection. (A) Experimental schematic for NK cell deple-
tion. At 3 and 1 days prior to infection with HSV-1 (performed as describe in Figure 1), mice were injected i.p. with 200 
μg αNK1.1 antibody or an isotype control. (B) Flow plots show NK cell depletion in the vagina 1 day after HSV-1 infection. 
Flow plots are gated on Ly6G- live cells. (C) IFN-γ was measured by ELISA from vaginal washes taken 1 d.p.i. (isotype, 
n = 15; αNK1.1, n = 15). (D) NK cell numbers in the vagina 1 d.p.i. (mock, n = 3; HSV-1, n = 7; HSV-2, n = 11). (E) Immuno-
fluorescent analysis of vaginal tissue sections from Ncr1mT/mG reporter mice at 1 day after HSV-1 or HSV-2 infection. NK 
cells are shown in green, HSV proteins (detected with Alexa Fluor 647) are shown in red, and nuclei are shown in blue. 
White arrowheads indicate luminal border of the epithelium. NK cell numbers were counted in infected areas (HSV-1, n 
= 30; HSV-2, n = 25) (F) and in areas proximal to infected areas (within 12 × 104 pixels, approximately 75 μm) (HSV-1, n = 
35; HSV-2, n = 25). (G). At least 2 infected areas were counted from 4 independent sections with 3 mice per group. Data 
are pooled from 2 (D–G) or 3 (B) independent experiments. Horizontal bars show mean (C, F, G) or geometric mean (D); 
error bars show ± SD. Statistical significant was measured by 2-tailed Student’s t test (C), 1-way ANOVA with Tukey’s 
multiple comparisons test (D), or Mann-Whitney U test (F and G). *P < 0.05, ****P < 0.001.
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Activation and effector differentiation of  T cells occurs earlier during HSV-1 infection than HSV-2 infection. To 
determine whether greater numbers of  mature DCs in the dLN after HSV-1 infection enhanced T cell 
responses, we measured T cell activation status and effector differentiation in the dLN after HSV-1 and HSV-
2 infection. Higher numbers of  both CD4+ and CD8+ T cells were present in the dLN at 2 days after HSV-1 
infection, compared with mock infection or HSV-2 infection (Figure 5A). Furthermore, in HSV-1–infected 
mice, a greater percentage of  both CD4+ and CD8+ T cells expressed CD69, an early activation marker, 
compared with T cells from mock-infected or HSV-2–infected mice (Figure 5B). Accordingly, a substantially 
higher number of  CD4+CD69+ and CD8+CD69+ T cells were present in the dLN after HSV-1 than HSV-2 
infection (Figure 5B). Infection with low-passage clinical isolates of  HSV-1 and HSV-2 also resulted in great-
er numbers of  both CD4+ and CD8+ T cells in the dLN (Supplemental Figure 9, A and B). The percentage of  
CD4+ T cells expressing CD69 was similar after infection (Supplemental Figure 9C), whereas the fraction of  
Figure 5. Rapid T cell activation occurs after vaginal HSV-1 infection. Infections were performed as described in Figure 2. (A) Total number of CD4+ T cells 
(left graph) and CD8+ T cells (right graph) at 2 d.p.i. in the dLN. (B) Plots show expression of CD69 on CD4+ (top) and CD8+ (bottom) T cells after HSV-1 (left) or 
HSV-2 (right) infection. Numbers indicate percentage of CD4+ or CD8+ T cells expressing CD69. Left graphs show frequency of CD69 expression in CD4+ (top) 
or CD8+ (bottom) T cells. Right graphs show number of CD69+CD4+ (top) or CD69+CD8+ (bottom) T cells. All data area at 2 d.p.i. in the dLN. (C–D) A total of 1 × 
106 CFSE-labeled, CD45.1+ gBT-I CD8+ T cells were adoptively transferred to congenic naive recipients 1 day before HSV-1 or HSV-2 infection. (C) Plot is gated 
on total CD8+ T cells and shows CFSE dilution of gBT-I cells at 3 d.p.i. in the dLN. Histogram shows an overlay of gBT-I cells after HSV-1 (black) or HSV-2 (red) 
infection. Left graph shows percentage of CFSE-undivided (CFSE-undiluted) gBT-I cells. Right graph shows percentage of CFSE-divided (CFSE-diluted) gBT-I 
cells. (D) Plots are gated on gBT-I CD8+ T cells from the dLN and show expression of T-bet (top) and granzyme B (bottom) 3 days after HSV-1 infection. Boxes 
are drawn around divided gBT-I cells. Histograms show T-bet and granzyme B expression in divided gBT-I cells after HSV-1 (black) or HSV-2 (red) infection. 
MFI of T-bet expression (top graph) or granzyme B expression in the divided gBT-I population (bottom graph) is shown. Data in A and B are pooled from 3 
independent experiments (HSV-1, n = 13; HSV-2, n = 12; mock, n = 7). Data in C and D are pooled from 2 independent experiments (HSV-1, n = 9; HSV-2, n = 10). 
Horizontal bars show mean, and all error bars show ± SD. Statistical significance in A and B was measured by 1-way ANOVA with Tukey’s multiple compari-
sons test. Statistical significance in A and B was measured by 2-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.
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CD8+ T cells expressing CD69 was higher after infection with HSV-1 compared with HSV-2 (Supplemental 
Figure 9D). Regardless of  the frequency of  CD69 expression, the total number of  both CD4+ (Supplemental 
Figure 9E) and CD8+ (Supplemental Figure 9F) T cells was higher after HSV-1 compared with HSV-2.
To determine whether increased CD69 expression at 2 d.p.i. resulted in more rapid onset of  the effector 
T cell response, we examined proliferation of  virus-specific T cells using T cell receptor (TCR) transgenic 
CD8+ T cells that recognize an epitope derived from glycoprotein B of  HSV (gBT-I) (43). Congenically 
marked CD45.1+ gBT-I cells were labeled with CFSE and adoptively transferred to female recipients. Recip-
ients were inoculated intravaginally with HSV-1 or HSV-2, and dilution of  CFSE was measured in the dLN 
at 3 d.p.i. (Figure 5C). Whereas the majority of  CFSE-labeled gBT-I cells had undergone at least 1 cell 
division in HSV-1–infected mice, a high proportion of  CFSE-labeled gBT-I cells remained undivided in 
HSV-2–infected mice at this time point (Figure 5C). When divided cells were evaluated for upregulation 
of  the transcription factor T-bet and the cytolytic granule granzyme B to assess effector differentiation, we 
found that the expression levels of  both molecules were higher in gBT-I cells responding to an HSV-1 than 
Figure 6. Greater numbers of IFN-γ–producing T cells accumulate in the vagina after HSV-1 but not HSV-2 infection. Infections were performed as 
described in Figure 2. (A) IFN-γ–producing CD4+ (left) and CD8+ (right) T cells were assessed after HSV-1 (top row) or HSV-2 (bottom row) infection at 4 
d.p.i. in the vagina. Plots are gated on live CD3+CD4+ cells (left) or live CD3+CD8+ cells (right) after excluding NK cells and neutrophils. Number in plots 
shows frequency of IFN-γ+ cells in the CD4+ or CD8+ T cell populations. Frequency and total number of CD4+ T cells (B), as well as frequency (left) and 
number (right) of IFN-γ+CD4+ T cells (D) in the vagina at 4 d.p.i. are shown. Frequency and total number of CD8+ T cells (C), as well as frequency (left) 
and number (right) of IFN-γ+CD8+ T cells (E) in the vagina at 4 d.p.i. are shown. (F) IFN-γ was measured by ELISA assay in vaginal washes collected 
from virus- or mock-infected mice at day 4. Data are pooled from 2 independent experiments (HSV-1, n = 9; HSV-2, n = 9). Horizontal bars show mean; 
all error bars show ± SD. Statistical significance in B–E was measured by 2-tailed Student’s t test. Statistical significance in F was measured by 1-way 
ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.
 
9insight.jci.org   https://doi.org/10.1172/jci.insight.134258
R E S E A R C H  A R T I C L E
HSV-2 infection (Figure 5D). Thus, T cells are activated and acquire features of  effector T cells more rapidly 
after vaginal HSV-1 than HSV-2 infection.
HSV-1 infection leads to greater IFN-γ production and more rapid accumulation of  IFN-γ–producing T cells at 
sites of  infection than HSV-2. We next tested whether the rapid T cell activation after HSV-1 infection resulted 
in earlier accumulation of  effector T cells at the primary site of  infection. IFN-γ is crucial for controlling 
Figure 7. T cells and IFN-γ are critical for reducing neuronal viral burden after HSV-1 but not HSV-2 infection. (A) 
Eight-week-old C57BL/6J female mice were treated with Depo-Provera. Mice were injected i.p. with a combination 
of CD4+ and CD8+ T cell–depleting antibodies or with an isotype control at 1 and 3 days prior to and 1 d.p.i. (B) 
Representative plots show efficiency of T cell depletion at 6 d.p.i. in vagina. Top row shows isotype control; bottom 
shows mice treated with depleting antibodies. Left columns of plots are gated on live, NK1.1– cells and show CD4+ (left 
2) and CD8+ (middle 2) T cells with corresponding FMO controls. Right column of plots are gated on total live cells from 
the vagina and show the presence or absence of HSV-specific T cells. (C) Replicating virus was measured by plaque 
assay in vaginal washes collected on 2 (left graph) or 6 (right graph) d.p.i. from T cell–depleted (n = 9) or isotype-
treated controls (n = 10). (D) Replicating virus was measured by plaque assay in the lumbar-sacral DRG at 6 d.p.i. from 
T cell–depleted or isotype-treated controls. (E) Replicating virus was measured by plaque assay at 2 (left graph) and 
6 (right graph) d.p.i. in vaginal washes from IFN-γR CKO (n = 6-7) or littermate controls (n = 5–6). (F) Replicating virus 
was measured by plaque assay at 6 d.p.i. in lumbar-sacral ganglia IFN-γR CKO or littermate controls. Data are pooled 
from 3 (A–D) or 2 (E–F) independent experiments. Horizontal lines show mean; vertical bars show 95% CI. Statistical 
significance was measured by 2-way ANOVA with Bonferroni multiple comparisons test on log-transformed data. *P < 
0.05, **P < 0.01, ***P < 0.005, ****P < 0.001. 
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against HSV infection in multiple tissues, including neurons (21, 24, 44, 45), and — after the first few days 
of  infection — is predominantly produced by T cells (40). We hypothesized that T cells would need to act 
rapidly after HSV-1 infection to confer neuroprotection. As T cells had already begun to differentiate into 
effector T cells within the dLN at 3 d.p.i., we assessed the influx of  IFN-γ–producing cells into the vagina 
4 days after HSV-1 or HSV-2 infection. Due to the difficulty in evaluating virus-specific T cells so early in 
the primary response, we stimulated vaginal T cells with PMA and ionomycin to assess their capacity for 
IFN-γ production (Figure 6A). Although total vaginal CD4+ T cell numbers were not different after HSV-1 
and HSV-2 infection (Figure 6B and Supplemental Figure 3B), a higher frequency and number of  CD4+ 
T cells produced IFN-γ after HSV-1 infection (Figure 6, A and D). In contrast, whereas the proportion of  
CD8+ T cells that produced IFN-γ was similar between the 2 HSV infections (Figure 6, A and E), the total 
number of  CD8+ T cells and the number of  IFN-γ–producing CD8+ T cells was greater after HSV-1 than 
after HSV-2 infection (Figure 6, C and E, and Supplemental Figure 3B). To determine whether the greater 
number of  IFN-γ–producing T cells resulted in higher levels of  IFN-γ secretion in the vagina after HSV-1 
infection compared with HSV-2 infection, we measured cytokine levels in the lumen and found increased 
IFN-γ secretion in the vagina after HSV-1 infection compared with HSV-2 infection (Figure 6F). Thus, we 
find that accelerated T cell activation after HSV-1 infection results in greater accumulation of  T cells com-
petent for IFN-γ production and the potential for robust early cytokine secretion at sites of  viral replication.
The primary T cell response and neuronal responses to IFN-γ are required for neuroprotection against HSV-1 but not 
HSV-2 infection. We next tested whether the rapid T cell response elicited after HSV-1 infection contributed 
to control of  viral infection within the ganglia. Mice were injected i.p. with depleting antibodies against 
CD4+ and CD8+ T cells and then inoculated intravaginally with HSV-1 or HSV-2 (Figure 7A). At 6 d.p.i., 
we measured the efficacy of  T cell depletion (Figure 7B) and viral replication in the ganglia (Figure 7D). 
Mucosal titers were monitored throughout infection (Figure 7C). While shedding of  HSV-1 and HSV-2 into 
the vaginal lumen was similar regardless of  the presence or absence of  T cells at 2 d.p.i., a time point that is 
expected to be unaffected by the T cell response, there was a clear increase in mucosal titers of  both HSV-1 
and HSV-2 at 6 d.p.i. (Figure 7C). When viral replication was measured in the ganglia, there was a substan-
tial increase in the amount of  replicating HSV-1 within the ganglia compared with T cell–sufficient controls, 
in the absence of  T cells (Figure 7D). In contrast, the impact of  T cell depletion on HSV-2 replication within 
the ganglia was markedly smaller (Figure 7D), despite the increase in mucosal titers (Figure 7C). Thus, our 
data demonstrate that HSV-1 induces a potent, rapid T cell response that inhibits viral replication in the gan-
glia, in contrast to HSV-2 infection in which T cell control of  viral replication in the ganglia is less effective.
We next investigated the mechanism by which the primary T cell response confers protection against 
HSV-1 infection of  the ganglia. To determine whether IFN-γ was important for suppressing HSV-1 repli-
cation in the ganglia, we generated mice in which IFN-γR expression was abrogated specifically in periph-
eral neurons by breeding IFN-γRfl/fl × Advillin-Cre mice (IFN-γR CKO) (46–48). IFN-γR CKO mice 
or Cre-negative littermate controls were inoculated intravaginally with HSV-1 or HSV-2. Mucosal viral 
shedding was monitored throughout infection (Figure 7E), and at 6 d.p.i., we measured viral titers in the 
ganglia (Figure7F). Viral shedding into the vaginal mucosa was equivalent between all groups at 2 d.p.i., 
as expected (Figure 7E). Notably, we observed only minor differences in mucosal HSV-1 and HSV-2 shed-
ding between IFN-γR CKO mice and littermate controls at 6 d.p.i. (Figure 7E), which correlated with 
similar IFN-γR expression in the vagina between these 2 cohorts (Supplemental Figure 10). Despite this, 
the amount of  viral replication in the ganglia was significantly higher in HSV-1–infected IFN-γR CKO 
mice when compared with littermate controls, whereas ganglia titers of  HSV-2–infected IFN-γR CKO and 
littermate controls were similarly high (Figure 7F), suggesting that increased levels of  replicating HSV-1 
in the ganglia occur independently of  effects on mucosal replication. Thus, neuronal IFN-γ–mediated 
antiviral responses can limit HSV-1 viral replication in the ganglia but fail to control HSV-2.
Discussion
In this study, we report differences in the kinetics of  the T cell response between HSV-1 and HSV-2 vaginal 
infection, and we reveal an unexpected T cell–dependent mechanism for regulating neuronal replication 
after HSV-1 but not HSV-2 infection. We found that both CD4+ and CD8+ T cells display robust, early 
activation after HSV-1 infection, which led to more extensive proliferation of  virus-specific CD8+ T cells 
early during the course of  HSV-1 infection and faster acquisition of  effector T cell features. Our data show 
that disparities in the kinetics of  T cell activation correlate with increased accumulation of  mature DCs 
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within the dLN after HSV-1 infection, which in turn was dependent on rapid, NK cell–dependent IFN-γ 
production very early after HSV-1 but not HSV-2 inoculation. The accelerated T cell response after HSV-1 
infection was important for suppressing viral replication in the ganglia and was specific to HSV-1, as T cell 
depletion had only a minor impact on HSV-2 viral replication in the nervous system. Control of  HSV-1 
ganglionic infection was also dependent on neuronal responsiveness to IFN-γ, and our evidence implies 
that the IFN-γ required for neuroprotection was provided by T cells. Together, our data suggest a model in 
which a rapid T cell response elicited after HSV-1 infection drives a protective IFN-γ–mediated antiviral 
program in the peripheral nervous system, likely before viral invasion occurs or becomes too severe, while 
primary T cell responses occur too slowly after HSV-2 infection to subdue neuronal infection.
While HSV-1 and HSV-2 are closely related and display similar pathogenesis and cellular tropism, the 
early host-pathogen interactions that drive differences in disease are incompletely understood. While it is 
likely that multiple host-pathogen interactions influence the aggressive reactivation patterns of  HSV-2, our 
study suggests that T cell–dependent regulation of  HSV replication in the neurons during primary infection 
may contribute to differences in disease outcome between HSV-1 and HSV-2 by determining the extent 
of  viral replication in the ganglia and, ultimately, the size of  the latent reservoir. Studies using attenuated 
strains of  HSV or antiviral intervention have demonstrated a direct relationship between viral replication 
spread through the ganglia and the number of  latently infected neurons, which in turn correlates with in 
vivo reactivation (13, 49). Both HSV-1 and HSV-2 contain variations in genomic sequence, both between 
laboratory strains (50, 51) and clinical isolates (52–54). A recent study interrogating sequence variations 
in HSV-2 isolated from infected neonates showed a correlation between disease presentation and genomic 
diversity in viral proteins associated with neurovirulence in animal models, suggesting that these variations 
have a strong impact on pathogenesis and interaction with host cells (54). The specific virus-host interac-
tions that promote differences in the initiation of  the adaptive immune response after HSV-1 and HSV-2 are 
currently unknown. It will be important to understand whether genetic diversity among HSV strains results 
in the expression of  viral proteins that differentially modulate host immune responses, thus leading to dis-
parate disease outcomes. While the 2 strains of  HSV-1 and 2 strains of  HSV-2 that we used had similar host 
response phenotypes, and previous studies using HSV-1 strain KO have also reported comparable findings 
(55), we acknowledge that our conclusions will need to be corroborated with a broader panel of  laboratory 
strains or clinical isolates of  HSV-1 and HSV-2.
Delays in the inflammatory response of  the genital tract after vaginal inoculation with HSV-2 (37), 
as well other RNA viruses (36), have been reported, suggesting that there is a general lag in the antiviral 
response at the vaginal mucosal surface or that many viruses can successfully suppress antiviral responses 
in this tissue. Furthermore, after vaginal exposure to RNA viruses, DC maturation and subsequent cytotox-
ic T cell responses are slow compared with those elicited after i.p. inoculation (36), with activation kinetics 
similar to our own observations for HSV-2. Although we did not detect any IFN-α or IFN-β and relatively 
low levels of  IFN-λ after either HSV-1 or HSV-2 infection, IFN-γ was robustly produced from an unknown 
source only after HSV-1 infection. Thus, it appears that HSV-1, unlike HSV-2 or other tested viruses, is 
unable to suppress or evade a type II IFN response at the vagina. IFN-γ production occurs in 2 waves after 
HSV-2 infection (39, 40). The first wave of  IFN-γ, which occurs at 2 d.p.i., is largely driven by NK cells 
(39, 41). Our data demonstrate that early IFN-γ production after HSV-1 infection is also dependent on NK 
cells or ILC1s, a related innate lymphocyte, either through direct cytokine secretion or induction from other 
another cell type. Whether HSV-1 is directly stimulating NK cells through a pattern recognition receptor 
(56) or through induction of  other proinflammatory cytokines (57) is unknown. However, an important 
feature that distinguishes HSV-1 from HSV-2 infection appears to be the localization of  NK cells to areas of  
infected vaginal epithelium, which suggests differences in NK cell homing within the vagina. The chemok-
ine CXCL10, a ligand for CXCR3, has been reported to be induced within 24 hours after genital HSV infec-
tion, prior to type I IFN production (37). Thus, we hypothesize that differential induction of  CXCL10 very 
early after HSV-1 or HSV-2 by infected epithelial cells or other resident cell types, including stimulated DCs 
(58), may drive differences in NK cell localization and, ultimately, IFN-γ production. CXCL10 expression 
was linked to O-glycosylation of  the virion surface (37), which implies a potential role for glycosylated viral 
surface proteins in determining the kinetics of  the innate host response after HSV-1 or HSV-2 infection.
The activation of DCs, acquisition of viral antigens, and migration into the dLN are crucial for initiating 
antiviral T cell responses, and our data indicate that these events are differentially regulated after HSV-1 and 
HSV-2 infection in an IFN-γ–dependent manner. It unclear whether IFN-γ is acting directly on DCs to induce 
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maturation (59) or inducing the production of DC maturation factors by stimulating other cell types such as 
macrophages. While rapid IFN-γ induction appears to be a key difference between HSV-1 and HSV-2 infection, 
there may be other pathways that lead to disparate rates of DC maturation. One possibility is that the activity 
of DCs is impaired by direct infection after HSV-2 inoculation, as there is evidence to suggest that HSV can 
infect DCs and other antigen-presenting cells in vitro (60–62). However, there is currently little in vivo data 
showing HSV infection of DCs. Careful measurement of viral DNA by PCR in dLNs during the first few days 
of infection with an attenuated strain of HSV-2 detected little to no DNA within the whole dLN nor within DC 
populations isolated from the dLN (63, 64), suggesting that DCs relevant for T cell stimulation are not directly 
infected. However, it is possible that any directly infected DCs may undergo cell death prior to migration and 
may provide a source of viral antigens for other DCs that carry these antigens to the dLN. HSV does not appear 
to drain directly into the LN (64–66); thus, it seems unlikely that infection of leukocytes drives the differences in 
migration and maturation status of DCs after HSV-1 or HSV-2 infection. Instead, our data suggest that distinct 
inflammatory microenvironments in the vagina lead to slower DC maturation after HSV-2 infection.
The tissue-specific tropism of  HSV-1 and HSV-2 raises questions as to whether the differences in 
immune responses we observe after vaginal infection also occur after other routes of  inoculation. HSV-1 
infection can cause recurrent disease and significant pathology when introduced into the host through the 
skin, oral mucocutaneous, or corneal tissues. It is unclear whether similar host-pathogen interactions as we 
have observed in the vagina are also occurring at these susceptible sites of  infection. Further study will be 
required to determine whether HSV-1 elicits a similarly rapid response after other routes of  infection and 
whether T cells are equally capable of  mediating neuroprotection against HSV-1 at peripheral nervous sys-
tem sites other than the sacral and lumbar DRG.
Interest in understanding the requirements for neuroprotection against HSV is considerable due to the 
implications for both prophylactic and therapeutic vaccine design. Numerous studies have emphasized the 
importance of  memory CD8+ T cells in controlling HSV infection of  the ganglia against a vaginal challenge 
(26), as well as during reactivation (14, 27). Other studies have also revealed a role for memory CD4+ T 
cells via an antibody-dependent mechanism in protecting the ganglia from infection (25). While memory T 
cells are demonstrably important in the context of  HSV vaccine design (67) and in restricting mucosal viral 
replication during recurrent disease (19, 68), the role of  the primary T cell response in controlling neuronal 
infection is less understood. Our data show that primary T cell responses are required for mucosal control of  
both HSV-1 and HSV-2 infection but are only effective at suppressing HSV-1 replication in the ganglia. It is 
unclear why HSV-2 infection of  the ganglia is resistant to T cell–mediated control. One possibility is that the 
mechanisms for T cell–dependent HSV control in the nervous system and in the mucosa are different, and 
indeed, previous studies have highlighted the importance of  cellular pathways such as autophagy in subduing 
HSV infection specifically within the neuronal compartment (69). HSV encodes numerous viral proteins that 
suppress or evade host antiviral mechanisms (70), particularly in the nervous system (69, 71, 72). Thus, there 
may be a window within which to activate these antiviral pathways within the ganglia to provide efficient 
control of  infection, before the production of  these viral proteins. Indeed, at higher vaginal inoculation doses, 
HSV-1 leads to toxic megacolon through a neuronal route of  spread to the gut, suggesting that introduction 
of  a large bolus of  virus can lead to immediate dissemination into the peripheral nervous system, thus over-
coming T cell–mediated protection (73). The specific mechanisms that lead to neuroprotection against HSV-1 
are currently unknown, and further studies will be required to distinguish between the antiviral contributions 
of  CD4+ and CD8+ T cells. As our depletion strategy may have also depleted other CD4- and CD8-expressing 
cells such as DCs, it possible that these populations may also independently affect neuroprotection against 
HSV. The importance of  neuronal STAT1 signaling in conferring protection against HSV-1 corneal infection 
has previously been demonstrated (74), and our study suggests that IFN-γ signaling may be an important 
contributor to the induction of  STAT1-mediated antiviral pathways. Based on our findings, we hypothesize 
that T cell responses after HSV-1 infection are fast enough to induce IFN-γ–dependent antiviral mechanisms 
in the ganglia (75) that ultimately lead to rapid control of  infection, whereas the T cell responses after HSV-2 
infection fall outside the requisite window. Although we measure IFN-γ levels only in the vagina, it is possible 
that there is also rapid T cell–mediated IFN-γ production in the ganglia, and further studies will be required 
to determine whether cytokine secretion at both sites is required to confer robust neuroprotection. Altogether, 
our study reveals a critical role for T cells in determining the extent of  neuronal viral replication after HSV-1 
and HSV-2, and it implicates the primary adaptive immune response as an unexpected factor that could regu-
late the size of  the latent reservoir and, thus, the frequency of  recurrent disease during genital herpes.
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Methods
Animals. Six-week-old C57BL/6J mice were purchased from the Jackson Laboratory, rested for at least 1 week, 
and infected at a minimum of 8 weeks of age. Ifngr1fl/fl mice (48), provided by R.D. Schreiber (Washington Uni-
versity), were bred to Advillin-Cre mice (the Jackson Laboratory) (47) to generate Ifngr1fl/fl × Advillin-Cre females 
and Cre-negative female littermate controls. Litters were screened by PCR. gBT-I TCR transgenic mice specific 
for the glycoprotein B epitope gB (protein peptide 498-505) (43) were provided by F.R. Carbone (University 
of Melbourne, Melbourne, Australia) and W.R. Heath (University of Melbourne) and bred to B6.SJL-Ptprca 
Pepcb/BoyJ mice (the Jackson Laboratory). RosamT/mG mice were provided by W. Yokoyama (Washington Uni-
versity) (42). IFN-λR–deficient mice were provided by M.T. Baldridge (Washington University) and previously 
described (76); briefly, these mice were established by interbreeding Ifnlr1tm1a(EUCOMM)Wtsi mice and Deleter-Cre 
mice, followed by backcrossing by speed congenics onto a C57BL/6J background.
Viruses. HSV-1 McKrae (77), HSV-1 ATCC-2011-9 (ATCC VR-1789), HSV-2 186 syn+ (78), and HSV-
2 ATCC-2011-4 (ATCC VR-1781) were all propagated and titered in Vero cells (African green monkey 
kidney epithelial cells, ATCC) as previously described (26). All tissue culture experiments were performed 
under BSL2 containment.
Animal infection studies. All mice were injected s.c. in the neck once with 2 mg of  DMPA (Depo-Provera, 
Pfizer) 5–7 days prior to primary virus inoculation. For experiments in which T cells were depleted, mice 
were i.p. injected with 200 μg each of  αCD4 (clone GK1.5, Leinco Technologies) and αCD8 (clone YTS-
169.4, Leinco Technologies) at 1 and 3 days prior to infection and 1 d.p.i. Controls were treated with 400 
μg of  rat IgG2b isotype antibody (Leinco Technologies) on the same schedule. For experiments in which 
NK cells were depleted, mice were i.p. injected with 200 μg of  αNK1.1 (clone PK136, Leinco Technolo-
gies) at 1 and 3 days prior to infection. Controls were treated with 200 μg of  mouse IgG2a isotype antibody 
(Leinco Technologies) on the same schedule. Five to 7 days after DMPA injection, mice were intravaginally 
inoculated with 10 μL of  volume of  1 × 104 PFU of  virus. A sterile calginate swab moistened with sterile 
PBS was used to gently remove mucous from the vaginal cavity. A pipette tip was inserted into the vagina to 
deliver the 10 μL viral inoculum. Mock-infected animals were inoculated with sterile PBS (vehicle). IFN-γ 
was neutralized after HSV-1 infection by intravaginal inoculation with 100 μg αIFN-γ antibody (clone 
R4-6A2, BioXCell) or with a rat IgG1 isotype control (clone HPRN, BioXCell) 1 d.p.i.
For adoptive transfer of  CFSE-labeled gBT-I CD8+ T cells, CD8+ T cells were isolated from spleens 
of  CD45.1+ gBT-I TCR Tg mice by magnetic bead sorting (Stem Cell Technologies). CD8+ T cells were 
then labeled with CFSE (Invitrogen) at 1 × 107 cells/mL at 37°C for 10 minutes. A total of  1 × 106 
CFSE-labeled gBT-I CD8+ T cells was adoptively transferred by retro-orbital injection into recipient 
mice 1 day prior to infection.
Disease was monitored daily and scored as follows: 0, no disease; 1, mild erythema; 2, hair loss around 
genitalia and appearance of  sores; 3, hunched posture and ruffled fur; 4, hindlimb paralysis; 5, moribund (26).
Cytokine measurement. To measure cytokine secretion into the vaginal lumen, two 50-μL washes with 
sterile PBS were collected using a pipette from each mouse just prior to infection and daily after infection. 
Washes were centrifuged to remove cells and mucus, and supernatants were snap-frozen on dry ice. ELISA 
was used to measure IFN-γ, IFN-λ (R&D), IFN-α (PBL Assay Science), and IFN-β (BioLegend) according 
to the manufacturer’s protocol. 
Virus quantification. For titration of  virus in the vaginal lumen, 50-μL washes with sterile PBS were 
collected using a pipette and a sterile calginate swab and diluted in 950 μL of  ABC buffer (0.5 mM CaCl2, 
0.5 mM MgCl2, 1% glucose, 1% FBS in PBS; Sigma-Aldrich). To measure viral burden in the ganglia, 
mice were perfused with a minimum of  15 mL of  PBS after sedation with ketamine and xylazine. Five 
pairs of  sacral and lumbar DRG were excised from each mouse and snap-frozen on dry ice. Ganglia were 
pulverized with a motorized pestle homogenizer in 100 μL of  ABC buffer and titered in a final volume of  
1 mL. Plaque assays were performed on Vero cells as described (26). To measure viral DNA in the ganglia, 
DNA was extracted from homogenized DRG using a DNeasy kit (Qiagen). Viral DNA was detected by 
qPCR using iTaq Universal Probes kit (Bio-Rad) using the following previously published primer/probes: 
forward, 5′-TCAGCGAGGATAACCTGGGA-3′; reverse, 5-GGGAGAGCGTACTTGCAGG-3′, probe: 
5′-/56-FAM/CCAGTCGTT/ZEN/TATCTTCACTAGCCGCAGGTA/3IABkFQ/-3′ (Integrated DNA 
Technologies) (79). qPCR was performed on a CFX Connect Real Time system (Bio-Rad).
Tissue processing and flow cytometry. All tissues were harvested from animals sedated with ketamine and 
xylazine and thoroughly perfused with a minimum of 15 mL of PBS. Vaginas and draining iliac lymph 
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nodes were processed as follows: tissue was cut into pieces and digested for 15 minutes at 37°C in 0.5 mg/
mL of Dispase II (Roche) in DPBS (MilliporeSigma). Tissues were then digested for 40 minutes (vagina) or 
25 minutes (lymph node) at 37°C with 0.5 mg/mL Collagenase D (Roche) and 15 μg/mL DNase I (Roche) 
in RPMI media (Thermo Fisher Scientific) with 10% FBS. Totals of  50 μL (vagina) or 30 μL (lymph node) 
of  sterile EDTA were added to each sample and incubated at 37°C for another 5 minutes. Tissues were then 
mechanically disrupted through a 70-μm cell strainer into single cell suspension using a 3 mL syringe plunger. 
To measure IFN-γ production, cell suspensions were incubated with 25 ng/mL PMA (MilliporeSigma) and 
0.5 μg/mL ionomycin (MilliporeSigma) for 7 hours at 37°C in the presence of  5 μg/mL brefeldin A (Mil-
liporeSigma). Intracellular staining was performed using the Cytofix/Cytoperm kit (BD Biosciences) or the 
True Nuclear Transcription Factor Buffer set (BioLegend). For cytokines, after surface staining, cells were 
fixed in fixation and permeabilization solution at room temperature (RT) for 20 minutes and then incubated 
with intracellular antibodies overnight in Perm Wash Buffer. For T-bet and granzyme B, after surface staining, 
cells were incubated in 1× Fix Buffer on ice for 30 minutes and incubated with intracellular antibodies in 1× 
Perm Wash (BD Biosciences) on ice for 1 hour. Cell counts were performed by adding Precision Count Beads 
(BioLegend) to samples prior to flow cytometric acquisition. Dead cells were excluded using the Fixable Aqua 
Dead Cell Stain kit (Molecular Probes). Numbers of  cell subsets were calculated by multiplying the total live 
cell count by the frequency of  each subset, as identified by flow cytometry. Tetramers were prepared with 
HSV gB protein peptide 498-505 (ABI Scientific) by the Center of  Human Immunology and Immunotherapy 
Programs at Washington University and conjugated to streptavidin-APC (Invitrogen). Tetramer staining was 
performed at 37°C for 20 minutes in PBS with 2% FBS. The following antibodies were used for this study: 
CD3 (clone 145-2C11), CD4 (clone GK1.5 or RM4-4), CD8a (clone 53-6.7), CD8b.2 (clone 53-5.8), CD69 
(clone H1.2F3), CD45.1 (clone A20), CD44 (clone IM7), CD19 (clone 1D3/CD19), IFN-γ (clone XMG1.2), 
granzyme B (clone GB12), T-bet (clone 4B10), CD119 (clone 2E2), CD11c (clone N418), I-A/I-E (clone 
M5/114.15.2), CD11b (clone M1/70), CD103 (clone 2E7), CD86 (clone GL-1), Ly6G (clone 1A8), Ly6C 
(clone HK1.4), NK1.1 (clone PK136), NKp46 (clone 29A1.4), and Armenian hamster IgG isotype control 
(Supplemental Table 1). All antibodies were purchased from BioLegend, except for the CD119 and Armenian 
hamster isotype control antibodies, which were purchased from eBioscience. Samples were acquired on an 
LSR Fortessa (BD Biosciences) and analyzed by FlowJo (Tree Star Inc.).
Histology and immunofluroscence. All tissues were harvested from animals sedated with ketamine and xyla-
zine and thoroughly perfused with a minimum of 15 mL of PBS and 20 mL of 4% paraformaldehyde. Tissues 
were embedded in paraffin and sectioned on a microtome at the Histology Core in the Developmental Biology 
department at Washington University. HSV infection was identified in sections using an anti-HSV antibody 
incubated overnight at 4°C (Dako, B0114) and a donkey anti–rabbit IgG-HRP antibody (Jackson ImmunoRe-
search, 711-036-15) incubated for 1 hour at RT, and it was then enzymatically visualized by 3,3′-diaminobenzi-
dine (DAB) enzyme reaction (Sigma-Aldrich). Sections were counterstained with H&E, and images were cap-
tured on a Zeiss Cell Observer inverted microscope with color camera. For immunofluorescent visualization of  
NK cells, Ncr1mT/mG mice were perfused with PBS and PLP fixative with 2% paraformaldehyde. Tissues were 
cryoprotected overnight in 30% sucrose, frozen in OCT, and cut on a cryostat as 7-μm sections. Sections were 
incubated with a primary anti-HSV antibody for 1 hour at RT (Dako), a secondary donkey anti–rabbit IgG 
antibody conjugated to Alexa Fluor 647 (Molecular Probes) for 1 hour at RT, and DAPI as a nuclear counter-
stain. Images were captured on a Zeiss Cell Observer inverted microscope with color camera. NK cells were 
quantified using ImageJ software (NIH). Briefly, each image was divided into a grid of 400 pixel squares (Sup-
plemental Figure 11). Squares that fell over infected areas, as denoted by HSV-antigen positivity, were marked, 
and GFP+ NK cells that fell within those infected areas were counted. To quantify NK cells outside infected 
epithelium, regions of lamina propria or epithelium that were within 12,000 pixels (3 squares) were considered 
to be proximal areas, and GFP+ NK cells that fell within those squares were counted. Total NK cell counts were 
then divided by total number of squares involved to obtain a frequency of NK cells/400 pixels squares.
Statistics. All data analysis was performed on Graphpad Prism8 software. Values were transformed by 
log10 to normalize distribution and variances. Viral titers were analyzed by 2-way ANOVA with a Bonfer-
roni post hoc test to correct for multiple comparisons, an unpaired 2-tailed Student’s t test, or a Mann-Whit-
ney U test for nonnormally distributed data. Kruskal-Wallis and Dunn’s multiple comparisons tests were 
used for ordinal disease score data. Cell number data was analyzed by 2-way ANOVA with Bonferroni post 
hoc test to correct for multiple comparisons or 1-way ANOVA with Tukey’s post hoc test to correct for mul-
tiple comparisons. All data show mean ± SD. P < 0.05 was considered statistically significant.
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and Use of  Laboratory Animals (National Academies Press, 2011). The protocols were approved by the IACUC 
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